Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 2
2013 1
2014 2
2015 1
2017 1
2018 2
2019 6
2020 6
2021 4
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study.
So-Ngern A, Jirajariyavej S, Thuncharoon H, Khunthupat N, Chantarojanasiri T, Montakantikul P. So-Ngern A, et al. Among authors: montakantikul p. Clin Transl Sci. 2023 Dec;16(12):2709-2718. doi: 10.1111/cts.13665. Epub 2023 Oct 28. Clin Transl Sci. 2023. PMID: 37853952 Free PMC article. Clinical Trial.
Comparison of the mathematical equation and trapezoidal approach for 24 h area under the plasma concentration-time curve calculation in patients who received intravenous vancomycin in an acute care setting.
Chanapiwat P, Paiboonvong T, Rattanaumpawan P, Montakantikul P. Chanapiwat P, et al. Among authors: montakantikul p. Pharmacol Res Perspect. 2023 Feb;11(1):e01046. doi: 10.1002/prp2.1046. Pharmacol Res Perspect. 2023. PMID: 36588162 Free PMC article.
Pharmacokinetic/pharmacodynamic (PK/PD) simulation for dosage optimization of colistin and sitafloxacin, alone and in combination, against carbapenem-, multidrug-, and colistin-resistant Acinetobacter baumannii.
Rodjun V, Montakantikul P, Houngsaitong J, Jitaree K, Nosoongnoen W. Rodjun V, et al. Among authors: montakantikul p. Front Microbiol. 2023 Nov 30;14:1275909. doi: 10.3389/fmicb.2023.1275909. eCollection 2023. Front Microbiol. 2023. PMID: 38098659 Free PMC article.
32 results